Summary
Novo Nordisk sued Eli Lilly, saying Eli Lilly made false claims in ads about their weight loss and diabetes drugs. Novo Nordisk says Eli Lilly used old data to make their drugs look better than Novo’s medicines.Key Facts
- Novo Nordisk filed a lawsuit against Eli Lilly in New Jersey federal court.
- The suit says Eli Lilly’s ads use outdated clinical trial data to compare their drugs Zepbound and Mounjaro with Novo’s Wegovy and Ozempic.
- The lawsuit claims Eli Lilly compared their highest drug doses to lower doses of Novo Nordisk’s drugs unfairly.
- Eli Lilly says its advertising is truthful, transparent, and based on scientific evidence.
- Novo Nordisk says the FDA approved newer, more effective doses of its drugs that Eli Lilly did not reference in its ads.
- The lawsuit states Eli Lilly mentions the higher dose of Wegovy only in small, unclear footnotes.
- Both companies are competing in the fast-growing market for weight loss drugs using GLP-1 medicines.
- A recent study shows 15% of U.S. adults have used GLP-1 drugs for weight loss, up from 12% the previous year.
